Safety, Tolerability, and Pharmacokinetics of CG2001 in Chinese Adult Male Subjects With Androgenetic Alopecia: A Randomized, Double-Blind, Placebo-Controlled, Single- and Multi-Dose, Phase 1 Clinical Study
February 2026
in “
Journal of Dermatological Treatment
”
Studysummary This research describes CG2001's promising safety profile and reduced systemic exposure as an alternative to finasteride, supporting its further development for androgenic alopecia treatment in future trials.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on tandfonline.com →